Immunic (NASDAQ: IMUX)
$1.22
(-3.2%)
-$0.04
Price as of April 26, 2024, 4:00 p.m. ET
Immunic Return vs. S&P
| 1 Year | 5 Year | 5 Year Annualized | Since IPO |
|---|
Immunic Company Info
Immunic, Inc. is a clinical-stage biopharmaceutical company, which develops a pipeline of selective oral immunology therapies aimed at treating chronic inflammatory and autoimmune diseases. It focuses on ulcerative colitis, Crohn’s disease, relapsing-remitting multiple sclerosis, and psoriasis. The firm’s products include IMU-838, IMU-935, and IMU-856. The company is headquartered in New York, NY.
News & Analysis
Featured Article
Why Immunic Plummeted by 21% on Thursday
Word of a new share issue made investors feel queasy.
Eric Volkman | Jul 15, 2021
Featured Article
Why Immunic Stock Is Soaring Today
An analyst says buy.
Prosper Junior Bakiny | Aug 26, 2020
Valuation
Related Stocks
Premium Investing Services
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.